(C) Reuters. FILE PHOTO: Syringes filled with a dose of the Moderna COVID-19 vaccine sit on a table during an employee vaccination at the Sarasota Memorial Hospital in Sarasota, Florida, U.S., September 24, 2021. REUTERS/Shannon Stapleton
(Reuters) -Moderna Inc on Tuesday said the U.S. Food and Drug Administration should authorize booster doses of its COVID-19 vaccine in fully vaccinated older adults and high-risk individuals.
The company said its data supports the public health benefit of a booster dose of its vaccine to restore immune response, while reducing the number of “breakthrough” infections in fully-vaccinated adults.
Moderna (NASDAQ:MRNA)’s comments were released in briefing documents ahead of a Thursday and Friday meeting of the FDA’s outside expert advisers to discuss booster doses of Moderna and Johnson & Johnson (NYSE:JNJ)’s COVID-19 vaccines.
Rival Johnson & Johnson on Tuesday also cited data showing increased protection after a booster dose, which it said could be either administered as early as two months after the original dose of its vaccine.
Moderna pushes for COVID-19 vaccine boosters in older adults, high-risk individuals
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.